Mercedes Montiel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mercedes Montiel has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Eugenio Jiménez
Departamento de Bioquímica y Biología Molecular, Universidad de Málaga, Boulevard Louis Pasteur 32, 29071 Málaga, Spain
8 shared publications- Enrique Pérez de la Blanca
Hospital Quironsalud. Assisted Reproduction Unit., Malaga, Spain
5 shared publications - Eugenio Jiménez
Department of Biochemistry and Molecular Biology, Malaga University, Malaga, Spain
3 shared publications Juan Quesada
Department of Biochemistry and Molecular Biology, University of Malaga, Boulevard Louis Pasteur 32, 29071 Malaga, Spain
3 shared publications- Loredana Urso
Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy
3 shared publications Santo Marsigliante
3 shared publications
Latest Publications
- Open Access
- 31 October 2011
- Published by Bioscientifica in Journal of Endocrinology
- Vol. 213 (1) , 25-36
The renin–angiotensin system in thyroid disorders and its role in cardiovascular and renal manifestations
Thyroid disorders are among the most common endocrine diseases and affect virtually all physiological systems, with an especially marked impact on cardiovascular and renal systems. This review summarizes the effects of thyroid hormones on the renin–angiotensin system (RAS) and the participation of the RAS in the cardiovascular and renal manifestations of thyroid disorders. Thyroid hormones are important regulators of cardiac and renal mass, vascular function, renal sodium handling, and consequently blood pressure (BP). The RAS acts globally to control cardiovascular and renal functions, while RAS components act systemically and locally in individual organs. Various authors have implicated the systemic and local RAS in the mediation of functional and structural changes in cardiovascular and renal tissues due to abnormal thyroid hormone levels. This review analyzes the influence of thyroid hormones on RAS components and discusses the role of the RAS in BP, cardiac mass, vascular function, and renal abnormalities in thyroid disorders.
- 31 October 2011
- Published by Bioscientifica in Journal of Endocrinology
- Vol. 213 (1) , 25-36
Open AccessThe renin–angiotensin system in thyroid disorders and its role in cardiovascular and renal manifestations
Thyroid disorders are among the most common endocrine diseases and affect virtually all physiological systems, with an especially marked impact on cardiovascular and renal systems. This review summarizes the effects of thyroid hormones on the renin–angiotensin system (RAS) and the participation of the RAS in the cardiovascular and renal manifestations of thyroid disorders. Thyroid hormones are important regulators of cardiac and renal mass, vascular function, renal sodium handling, and consequently blood pressure (BP). The RAS acts globally to control cardiovascular and renal functions, while RAS components act systemically and locally in individual organs. Various authors have implicated the systemic and local RAS in the mediation of functional and structural changes in cardiovascular and renal tissues due to abnormal thyroid hormone levels. This review analyzes the influence of thyroid hormones on RAS components and discusses the role of the RAS in BP, cardiac mass, vascular function, and renal abnormalities in thyroid disorders.
- 1 March 2010
- Published by Elsevier in Biochemical Pharmacology
- Vol. 79 (6) , 810-816
Effects of cisplatin on matrix metalloproteinase-2 in transformed thyroid cells
- 1 March 2010
- Published by Elsevier in Biochemical Pharmacology
- Vol. 79 (6) , 810-816
Effects of cisplatin on matrix metalloproteinase-2 in transformed thyroid cells
- 1 March 2009
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 380 (4) , 769-774
Angiotensin II induces MMP 2 activity via FAK/JNK pathway in human endothelial cells
- 1 March 2009
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 380 (4) , 769-774
Angiotensin II induces MMP 2 activity via FAK/JNK pathway in human endothelial cells
- Open Access
- 1 January 2009
- Published by S. Karger AG in Cellular Physiology and Biochemistry
- Vol. 23 (4-6) , 441-448
Cisplatin Reduces Endothelial Cell Migration Via Regulation of Type 2-Matrix Metalloproteinase Activity
In this study we investigated the effect of cisplatin on endothelial cell migration, an essential process for vascular remodeling and regeneration in several physiological and pathological situations. Human umbilical vein endothelial cells (HUVEC) were treated with cisplatin and endothelial cell migration analyzed by fluorescence and scratch-wound migration assay. MMP2 and MMP9 activity were determined by zymographic assay, and MAPK activation by Western blotting analysis. We demonstrated that cisplatin provoked a time- and dose-dependent decrease of HUVEC migration; this effect was clearly independent from its well known cytotoxic activity. In addition, cisplatin markedly reduced MMP2 activity in both conditioned media and cell lysates, increased p38 MAPK and JNK phosphorylation, but did not affect ERK phosphorylation. Endothelial cell migration was attenuated by treatment of cells with GM6001, a non-specific inhibitor of MMPs, or by a selective anti-MMP2 antibody. However, treatment of cells with SB202190 or SP600125, inhibitors of p38 MAPK and JNK respectively, did not affect HUVEC migration. These results suggested that cisplatin induced a reduction of endothelial cell migration through an inhibition of MMP2 activity by downstream signal transduction pathways independent of JNK and p38 MAPK activation.
- 1 January 2009
- Published by S. Karger AG in Cellular Physiology and Biochemistry
- Vol. 23 (4-6) , 441-448
Open AccessCisplatin Reduces Endothelial Cell Migration Via Regulation of Type 2-Matrix Metalloproteinase Activity
In this study we investigated the effect of cisplatin on endothelial cell migration, an essential process for vascular remodeling and regeneration in several physiological and pathological situations. Human umbilical vein endothelial cells (HUVEC) were treated with cisplatin and endothelial cell migration analyzed by fluorescence and scratch-wound migration assay. MMP2 and MMP9 activity were determined by zymographic assay, and MAPK activation by Western blotting analysis. We demonstrated that cisplatin provoked a time- and dose-dependent decrease of HUVEC migration; this effect was clearly independent from its well known cytotoxic activity. In addition, cisplatin markedly reduced MMP2 activity in both conditioned media and cell lysates, increased p38 MAPK and JNK phosphorylation, but did not affect ERK phosphorylation. Endothelial cell migration was attenuated by treatment of cells with GM6001, a non-specific inhibitor of MMPs, or by a selective anti-MMP2 antibody. However, treatment of cells with SB202190 or SP600125, inhibitors of p38 MAPK and JNK respectively, did not affect HUVEC migration. These results suggested that cisplatin induced a reduction of endothelial cell migration through an inhibition of MMP2 activity by downstream signal transduction pathways independent of JNK and p38 MAPK activation.
- 1 October 2007
- Published by Elsevier in Cellular Signalling
- Vol. 19 (10) , 2138-2146
Activation of calcium-dependent kinases and epidermal growth factor receptor regulate muscarinic acetylcholine receptor-mediated MAPK/ERK activation in thyroid epithelial cells
- 1 October 2007
- Published by Elsevier in Cellular Signalling
- Vol. 19 (10) , 2138-2146
Activation of calcium-dependent kinases and epidermal growth factor receptor regulate muscarinic acetylcholine receptor-mediated MAPK/ERK activation in thyroid epithelial cells
- 1 January 2006
- Published by S. Karger AG in Cellular Physiology and Biochemistry
- Vol. 18 (1-3) , 123-134
P2Y Receptors Activate MAPK/ERK Through a Pathway Involving PI3K/PDK1/PKC-ζ in Human Vein Endothelial Cells
In this study we investigated the effects of P2 receptors in the regulation of mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) in human umbilical vein endothelial cells (HUVEC). Cytosolic Ca(2+) concentration ([Ca(2+)](i)) was measured using fura-2/AM, and MAPK/ ERK phosphorylation using Western blot analysis. ATP, 2-meSATP, UTP and UDP cause a rapid and transitory increase in the phosphorylation of MAPK/ERK. In contrast, negligible response was seen for a,Beta-meATP, a general P2X receptors agonist. ATP-dependent activation of MAPK/ERK was prevented by pretreatment of HUVEC with pertussis toxin or MEK inhibitor PD98059. In addition, activation of the MAPK/ ERK cascade by ATP was blocked in cells pretreated with wortmannin and LY294002, but not by U73122, BAPTA or a Ca(2+)-free medium. Furthermore, an inhibition of ATP-dependent MAPK/ERK phosphorylation was observed in HUVEC pretreated with high doses of GF109203X or myristoylated PKC- zeta pseudosubstrate. Similar results were observed when cells were pretreated with the Src tyrosine kinase inhibitor PP2. However, ATP-stimulated MAPK/ERK activation was unaffected in cells pretreated with AG1478 or perillic acid. We also found that ATP stimulates both the phosphorylation of 3- phosphoinositide-dependent protein kinase-1 (PDK1) and its translocation to plasma membrane in a time-dependent manner. These observations suggest that the effects mediated by ATP in HUVEC occur via PTX-sensitive G-protein-coupled P2Y receptors through PI3K-dependent mechanisms, in which PDK1 and PKC-zeta are two key molecules within signal cascade leading to MAPK/ERK activation.
- 1 January 2006
- Published by S. Karger AG in Cellular Physiology and Biochemistry
- Vol. 18 (1-3) , 123-134
P2Y Receptors Activate MAPK/ERK Through a Pathway Involving PI3K/PDK1/PKC-ζ in Human Vein Endothelial Cells
In this study we investigated the effects of P2 receptors in the regulation of mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) in human umbilical vein endothelial cells (HUVEC). Cytosolic Ca(2+) concentration ([Ca(2+)](i)) was measured using fura-2/AM, and MAPK/ ERK phosphorylation using Western blot analysis. ATP, 2-meSATP, UTP and UDP cause a rapid and transitory increase in the phosphorylation of MAPK/ERK. In contrast, negligible response was seen for a,Beta-meATP, a general P2X receptors agonist. ATP-dependent activation of MAPK/ERK was prevented by pretreatment of HUVEC with pertussis toxin or MEK inhibitor PD98059. In addition, activation of the MAPK/ ERK cascade by ATP was blocked in cells pretreated with wortmannin and LY294002, but not by U73122, BAPTA or a Ca(2+)-free medium. Furthermore, an inhibition of ATP-dependent MAPK/ERK phosphorylation was observed in HUVEC pretreated with high doses of GF109203X or myristoylated PKC- zeta pseudosubstrate. Similar results were observed when cells were pretreated with the Src tyrosine kinase inhibitor PP2. However, ATP-stimulated MAPK/ERK activation was unaffected in cells pretreated with AG1478 or perillic acid. We also found that ATP stimulates both the phosphorylation of 3- phosphoinositide-dependent protein kinase-1 (PDK1) and its translocation to plasma membrane in a time-dependent manner. These observations suggest that the effects mediated by ATP in HUVEC occur via PTX-sensitive G-protein-coupled P2Y receptors through PI3K-dependent mechanisms, in which PDK1 and PKC-zeta are two key molecules within signal cascade leading to MAPK/ERK activation.
- 2 March 2005
- Published by Wiley in Journal of Cellular Physiology
- Vol. 204 (2) , 678-686
Activation of MAP kinase by muscarinic cholinergic receptors induces cell proliferation and protein synthesis in human breast cancer cells
Carbachol (Cch), a muscarinic acetylcholine receptor (mAChR) agonist, increases intracellular‐free Ca2+ mobilization and induces mitogen‐activated protein kinase/extracellular signal‐regulated kinase (MAPK/ERK) phosphorylation in MCF‐7 human breast cancer cells. Pretreatment of cells with the selective phospholipase C (PLC) inhibitor U73122, or incubation of cells in a Ca2+‐free medium did not alter Cch‐stimulated MAPK/ERK phosphorylation. Phosphorylation of MAPK/ERK was mimicked by phorbol 12‐myristate acetate (PMA), an activator of protein kinase C (PKC), but Cch‐evoked MAPK/ERK activation was unaffected by down‐regulation of PKC or by pretreatment of cells with GF109203X, a PKC inhibitor. However, Cch‐stimulated MAPK/ERK phosphorylation was completely blocked by myristoylated PKC‐ζ pseudosubstrate, a specific inhibitor of PKC‐ζ, and high doses of staurosporine. Pretreatment of human breast cancer cells with wortmannin or LY294002, selective inhibitors of phosphoinositide 3‐kinase (PI3K), diminished Cch‐mediated MAPK/ERK phosphorylation. Similar results were observed when MCF‐7 cells were pretreated with genistein, a non‐selective inhibitor of tyrosine kinases, or with the specific Src tyrosine kinase inhibitor PP2. Moreover, in MCF‐7 human breast cancer cells mAChR stimulation induced an increase of protein synthesis and cell proliferation, and these effects were prevented by PD098059, a specific inhibitor of the mitogen activated kinase kinase. In conclusion, analyses of mAChR downstream effectors reveal that PKC‐ζ, PI3K, and Src family of tyrosine kinases, but not intracellular‐free Ca2+ mobilization or conventional and novel PKC activation, are key molecules in the signal cascade leading to MAPK/ERK activation. In addition, MAPK/ERK are involved in the regulation of growth and proliferation of MCF‐7 human breast cancer cells.
- 2 March 2005
- Published by Wiley in Journal of Cellular Physiology
- Vol. 204 (2) , 678-686
Activation of MAP kinase by muscarinic cholinergic receptors induces cell proliferation and protein synthesis in human breast cancer cells
Carbachol (Cch), a muscarinic acetylcholine receptor (mAChR) agonist, increases intracellular‐free Ca2+ mobilization and induces mitogen‐activated protein kinase/extracellular signal‐regulated kinase (MAPK/ERK) phosphorylation in MCF‐7 human breast cancer cells. Pretreatment of cells with the selective phospholipase C (PLC) inhibitor U73122, or incubation of cells in a Ca2+‐free medium did not alter Cch‐stimulated MAPK/ERK phosphorylation. Phosphorylation of MAPK/ERK was mimicked by phorbol 12‐myristate acetate (PMA), an activator of protein kinase C (PKC), but Cch‐evoked MAPK/ERK activation was unaffected by down‐regulation of PKC or by pretreatment of cells with GF109203X, a PKC inhibitor. However, Cch‐stimulated MAPK/ERK phosphorylation was completely blocked by myristoylated PKC‐ζ pseudosubstrate, a specific inhibitor of PKC‐ζ, and high doses of staurosporine. Pretreatment of human breast cancer cells with wortmannin or LY294002, selective inhibitors of phosphoinositide 3‐kinase (PI3K), diminished Cch‐mediated MAPK/ERK phosphorylation. Similar results were observed when MCF‐7 cells were pretreated with genistein, a non‐selective inhibitor of tyrosine kinases, or with the specific Src tyrosine kinase inhibitor PP2. Moreover, in MCF‐7 human breast cancer cells mAChR stimulation induced an increase of protein synthesis and cell proliferation, and these effects were prevented by PD098059, a specific inhibitor of the mitogen activated kinase kinase. In conclusion, analyses of mAChR downstream effectors reveal that PKC‐ζ, PI3K, and Src family of tyrosine kinases, but not intracellular‐free Ca2+ mobilization or conventional and novel PKC activation, are key molecules in the signal cascade leading to MAPK/ERK activation. In addition, MAPK/ERK are involved in the regulation of growth and proliferation of MCF‐7 human breast cancer cells.
- 1 February 2005
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 327 (4) , 971-978
Angiotensin II induces focal adhesion kinase/paxillin phosphorylation and cell migration in human umbilical vein endothelial cells
- 1 February 2005
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 327 (4) , 971-978
Angiotensin II induces focal adhesion kinase/paxillin phosphorylation and cell migration in human umbilical vein endothelial cells
- 1 December 2003
- Published by Wiley in Signal Transduction
- Vol. 3 (5-6) , 201-208
Angiotensin II effect on calcium mobilization and mitogen‐activated protein kinase activation in human umbilical vein endothelial cells
- 1 December 2003
- Published by Wiley in Signal Transduction
- Vol. 3 (5-6) , 201-208
Angiotensin II effect on calcium mobilization and mitogen‐activated protein kinase activation in human umbilical vein endothelial cells
- 14 May 2002
- Published by Elsevier in Cellular Signalling
- Vol. 14 (8) , 665-672
Muscarinic activation of mitogen-activated protein kinase in rat thyroid epithelial cells
- 14 May 2002
- Published by Elsevier in Cellular Signalling
- Vol. 14 (8) , 665-672
Muscarinic activation of mitogen-activated protein kinase in rat thyroid epithelial cells